NEW YORK, March 6 - Amersham Biosciences and biotech firms Dyax and Affibody plan to co-develop affinity-based chromatographic media for large-scale protein separation and purification, Amersham said on Wednesday.
Terms of the agreement call for Dyax to give Amersham non-exclusive rights to its phage-display affinity-ligand discovery process, which designed to find ligands that may be used in chromatography separation. Amersham said it intends to use the technology for "specific customer needs and to develop more broadly applicable products for the protein separations field."
Meanwhile, Amersham and Affibody will develop a class of small affinity proteins, which the companies call Affibodies, designed to bind to desired protein targets.
Financial terms of the agreements were not disclosed.
"Through these deals, Amersham Biosciences will develop and commercialize new media products with high affinity, selectivity and capacity," Peter Ehrenheim, vice president of protein separations at Amersham Biosciences, said in a statement.
Dyax is based in Cambridge, Mass. Affinity has headquarters in Stockholm, Sweden.